Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Education On-Demand: Understanding How Biomarkers Help Guide Treatment Decisions for Those with CLL / SLL

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Recorded May 22, 2023

Each person who is diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL) has a unique set of genetic biomarkers that make their type of the cancer unique to them. Biomarker testing will give you and your healthcare provider a better understanding of what treatments will work best for your disease type (predictive factors) and help to determine how aggressive your risk of the disease might be over time (prognostic factors).

In this session, we will discuss the most common biomarkers found in CLL / SLL, when and how to test for them using CLL Society’s Test Before Treat™ educational resource as a guide, which biomarker test results can change over time, and how some CLL / SLL treatments won’t work as well when certain biomarkers are present. Additionally, we will explore how testing for MRD (measurable residual disease) might serve as a guide for knowing when to start or stop treatment. Don’t miss this informative session on the role of biomarkers in CLL / SLL.



Robyn Brumble photo

Robyn Brumble, MSN, RN
Director of Scientific Affairs & Research
CLL Society


Terry Evans - CLL Society

Terry Evans
23-year CLL Patient and Advocate
Director, CLL Society Support Network


Catherine Coombs - CLL Society

Catherine Coombs, MD
Associate Clinical Professor of Medicine
Chao Family Comprehensive Cancer Center
University of California, Irvine

This program was made possible by generous donors and grant support from AstraZeneca.